Email this article 
Analysis of factors affecting patient satisfaction with treatment for neovascular age-related macular degeneration
- Authors: Gorkavenko F.V.1,2,3, Goryachev A.B.2,3, Ratanova P.S.2,3,4
- Affiliations:
- Center for Healthcare Quality Assessment and Control, Moscow, Russia
- Sechenov First Moscow State Medical University, Moscow, Russia
- Russian Medical Academy of Continuous Professional Education, Moscow, Russia
- Eye Microsurgery Ekaterinburg Center, Ekaterinburg, Russia
- Issue: No 2 (2026)
- Pages: 122-127
- Section: Articles
- URL: https://remedium-journal.ru/journal/article/view/1913
- DOI: https://doi.org/10.32687/1561-5936-2026-30-2-122-127
- Cite item
Abstract
The widespread practice of self-discontinuation of treatment and low levels of treatment adherence among patients with neovascular age-related macular degeneration (nAMD) are among the common challenges in managing this disease, which underscores the need to study patient satisfaction with treatment and identify factors that enhance it. For this purpose, we have conduct survey among nAMD patients receiving specialized treatment with angiogenesis inhibitors, during which data were collected on factors potentially associated with treatment satisfaction. The relationship between these factors and satisfaction was assessed using logistic regression. The optimal logistic regression model included such factors as visual acuity dynamics over the past 6 months, patients' awareness of the disease and its treatment strategy, and the level of treatment adherence, and had a coefficient of determination (R2) equal to 0.38. In addition, satisfaction was also associated with having pensioner status and self-payment for treatment. As the main reasons for low satisfaction, patients most frequently cited the distance from their residence to the healthcare facility (24%), financial reasons (17 %), and unsatisfactory treatment outcomes (15%). Based on the study results, the relationship between treatment satisfaction and patients' level of treatment adherence was confirmed, and additional factors influencing satisfaction were identified.
About the authors
Filipp V. Gorkavenko
Center for Healthcare Quality Assessment and Control, Moscow, Russia; Sechenov First Moscow State Medical University, Moscow, Russia; Russian Medical Academy of Continuous Professional Education, Moscow, Russia
Email: fill-gor@yandex.ru
Andrey B. Goryachev
Sechenov First Moscow State Medical University, Moscow, Russia; Russian Medical Academy of Continuous Professional Education, Moscow, Russia; Sechenov First Moscow State Medical University, Moscow, Russia
Email: abgor61@gmail.com
Polina S. Ratanova
Sechenov First Moscow State Medical University, Moscow, Russia; Russian Medical Academy of Continuous Professional Education, Moscow, Russia; Eye Microsurgery Ekaterinburg Center, Ekaterinburg, Russia
Email: polina_zl@mail.ru
References
- Neroev V. V., Zaitseva O. V., Petrakovskaya V. A. et al. The first Russian register of patients with neovascular age-related macular degeneration: a real-world clinical study. Russian Ophthalmological Journal. 2023;16(4):7—26. (In Russ.)
- Bobykin E. V., Morozova O. V., Buslaev R. V. Duration of anti-VEGF therapy of neovascular macular diseases in real clinical practice. Practical medicine. 2017;(9):43—48. (In Russ.)
- Bobykin E. V., Korotkikh S. A., Krokhalev V. Ya. et al. Anti-VEGF therapy of wet age-related macular degeneration: analysis of patients lost to follow-up. Bulletin of Ophthalmology. 2021;137(2):66—74. (In Russ.)
- Bikbov M. M., Akhmerova S. G., Yakupova E. M. et al. Organization of ophthalmological care for age-related macular degeneration: problems and ways of improvement. Ufa; 2024. 148 p. (In Russ.)
- Bobykin E. V., Korotkikh S. A., Nerus I. A., Morozova O. V. Treatment satisfaction of patients with neovascular age-related macular degeneration receiving antiangiogenic therapy. Pacific Medical Journal. 2019;(2):14—18. (In Russ.)
- Bobykin E. V., Korotkikh S. A., Morozova O. V. et al. Results of the clinical application of the original questionnaire on treatment satisfaction in patients receiving anti-VEGF therapy for neovascular age-related macular degeneration. Effective pharmacotherapy. 2022;18(11):10—15. (In Russ.)
- Bobykin E. V. Antiangiogenic therapy in Russian ophthalmological practice: achievements, challenges, and solutions. Bulletin of the N. I. Pirogov National Medical and Surgical Center. 2025;20(4):168—174. (In Russ.)
- Gorkavenko F. V., Goryachev A. B., Ashikhmina O. V. et al. Marketing analysis of the Russian pharmaceutical market for treatment of neovascular age-related macular degeneration. Pharmaco-economics. Modern pharmacoeconomics and pharmacoepidemiology. 2025;18(2):184—198. (In Russ.)
- Bobykin E. V. The influence of patient compliance with antiangiogenic therapy on its efficacy for neovascular age-related macular degeneration. Bulletin of Ophthalmology. 2014;130(4):88—96. (In Russ.)
